Skip to main content

Table 8 A list of studies on systemic therapies and quality of life in breast cancer patients (1974–2007)

From: Health-related quality of life in breast cancer patients: A bibliographic review of the literature from 1974 to 2007

Author(s) [Ref.] Year Treatment/patients Conclusion(s)
Moore et al. [36] 1974 Adrenalectomy + chemotherapy in advanced breast cancer In most patients the subjective palliation involved a return to normal living.
Priestman and Baum [37] 1976 Chemotherapy in advanced breast cancer Toxicity is not related to the patients' age and diminished with successive courses of drugs.
Palmer et al. [114] 1980 A single agent vs. five drug combination in node positive primary breast cancer Better QOL in single agent group.
Coates et al. [115] 1987 Intermittent vs. continuous chemotherapy in metastatic breast cancer Continuous chemotherapy was better; changes in the QOL were independent prognostic factor of survival.
Kiebert et al. [116] 1990 Peri-operative chemotherapy vs. no chemotherapy in early stage breast cancer No differences 1 year after; patients considered chemotherapy most burdensome aspect of treatment.
Gelber et al. [117] 1991 Single cycle of combination chemotherapy vs. longer duration chemotherapy for pre-menopausal or chemo-endocrine therapy for postmenopausal women Better QOL in longer duration chemotherapy or chemo-endocrine therapy.
Berglund et al. [118] 1991 Late effects of adjuvant chemotherapy vs. postoperative radiotherapy in pre- and post-menopausal breast cancer Chemotherapy patients had higher overall QOL.
Richards et al. [119] 1992 A (weekly for 12 courses vs. every three weeks for 4 courses) in advanced breast cancer Similar survival but higher psychological distress in the three weeks group.
Hurny et al. [120] 1992 CMF (6 cycles vs. 3 cycles) in operable breast cancer QOL improved with increasing time from the study entry.
Campora et al. [121] 1992 Adjuvant chemotherapy vs. palliative chemotherapy in metastatic breast cancer No significant difference between groups.
Fraser et al. [122] 1993 CMF vs. E in advanced breast cancer Similar survival and no significant difference in overall global QOL.
Twelves et al. [123] 1994 Iododoxorubicin in advanced breast cancer Little evidence of benefit in terms of physical symptom relief, level of activity, psychological symptoms or global QOL.
Bertsch and Donaldson. [124] 1995 Vinorelbine vs. melphalan Vinorelbine was better in some aspects of QOL.
Swain et al. [125] 1996 AC + G-CSF in node positive breast cancer Tolerable physical symptoms and emotional distress.
McQuellon et al. [126] 1996 High-dose chemotherapy + ABMT No significant difference between pre- and post-treatment QOL.
Larsen et al. [127] 1996 High-dose chemotherapy + ASCT Resulting in poor physical and emotional health.
Hurny et al. [128] 1996 6 cycles of CMF vs. 3 cycles CMF in node-positive operable breast cancer Worse QOL during treatment but not after treatment completion.
Griffiths and Beaver [129] 1997 High-dose chemotherapy in advanced breast cancer No significant deterioration in QOL.
Lindley et al. [130] 1998 Systemic adjuvant therapy 2–5 years after treatment good QOL. Small to modest gain was acceptable to women.
Ganz et al. [131] 1998 TAM or chemotherapy alone or chemotherapy + TAM, or no adjuvant therapy No significant differences in global QOL among treatment groups; those who received chemotherapy had more sexual problems and those who received TAM had more vasomotor symptoms.
Bernhard et al. [132] 1999 Formestane vs. megestrol acetate in postmenopausal advanced breast cancer while on TAM No significant difference in QOL; baseline QOL was strong predictive for QOL under treatment but not for time to treatment failure.
Fairclough et al. [133] 1999 CAF vs. dose intensive a 16-week multi-drug regimen Negative impact of the dose intensive 16-week regimen was observed, although Q-TwiST analysis showed a small gain for this regimen.
Osoba and Burchmore [134] 1999 Trastuzumab (Hercptin) in metastatic breast cancer who may or may not have had prior chemotherapy Trastuzumab was associated with an amelioration of the deleterious effects of chemotherapy alone; the drug was not associated with worsening of QOL.
McLachlan et al. [135] 1999 Chemotherapy in metastatic breast cancer QOL maintained or improved; patients did not want to trade quantity for QOL.
Macquart-Moulin et al. [136] 2000 High-dose chemotherapy + G-CSF + ASCT in inflammatory breast cancer QOL deterioration disappeared after treatment and returned to baseline after one year.
Riccardi et al. [137] 2000 Doubling E within FEC vs. FEC in metastatic breast cancer No significant difference in response or improvement of baseline QOL.
Kramer et al. [138, 139] 2000 Paclitaxel vs. A in advanced breast cancer QOL appeared to be prognostic for survival and response to treatment.
Joly et al. [140] 2000 CMF + irradiation vs. irradiation in pre-menopausal breast cancer Similar QOL was observed.
Hakamies-Blomqvist et al. [141] 2000 T vs. sequential MF in metastatic breast cancer Difference in QOL was minor favoring MF.
Broeckel et al. [142] 2000 Adjuvant chemotherapy treated breast cancer (after 3 to 36 months) Younger age, unmarried status, time since diagnosis and chemotherapy completion related to greeter depressive symptoms.
Carlson et al. [143] 2001 High-dose chemotherapy + ASCT in metastatic breast cancer Anxiety and depression continued to increase, loss of sexual interest, worrying and joint pain were reported.
Osoba et al. [144] 2002 Chemotherapy + Trastuzumab (Hercptin) vs. Chemotherapy alone in metastatic breast cancer More improved global QOL with chemotherapy + Herceptin.
Modi et al. [145] 2002 Paclitaxel in metastatic breast cancer QOL benefit in tumor response patients.
Heidemann et al [146]. 2002 Mitoxantrone vs. FEC in metastatic breast cancer No significant difference in survival or response but a QOL scores favored mitoxantrone.
Genre et al. [147] 2002 High-dose-intensity AC (21 vs. 14 days) Shortening cycles had a high negative impact on QOL.
de Haes et al. [148] 2003 Goserelin vs. CMF in peri-and pre-menopausal node-positive early breast cancer Better QOL in favor of goserelin.
Brandberg et al. [149] 2003 Tailored FEC vs. induction FEC followed with high-dose CTCb + peripheral SCT No significant overall differences were found between groups.
Land et al. [150] 2004 CMF vs. AC in axillary node negative and estrogen receptor negative breast cancer Overall QOL was equivalent between two groups.
Fallowfield et al. [151] 2004 ANA vs. TAM alone or in combination in postmenopausal early breast cancer Similar overall QOL impact but some small differences in side effects profiles.
Bottomely et al. [152] 2004 AT vs. AC in metastatic breast cancer No significant differences in QOL between two groups.
Bernhard et al. [153] 2004 TAM for 5 years or three prior cycles of CMF followed by 57 months TAM in estrogen receptor-negative and estrogen receptor-positive breast cancer At completion there were no differences by treatment groups.
Tong et al. [154] 2005 Capecitabine, idarubicin and cyclophosphamide (all-oral regimen, XIC) in metastatic breast cancer No significant decease in global QOL scores.
Galalae et al. [155] 2005 Radiotherapy and adjuvant chemotherapy vs. radiotherapy and hormonal therapy vs. radiotherapy alone after conserving surgery Adjuvant chemotherapy lowered QOL vs. hormones or radiotherapy alone.
Elkin et al. [156] 2005 Ovarian suppression vs. chemotherapy in pre-menopausal hormone-responsive breast cancer Assuming equal efficacy ovarian suppression was superior. Efficacy would have impact on treatment choice.
Conner-Spady et al. [157] 2005 High-dose chemotherapy + ABST in breast cancer with poor prognosis Impaired QOL in short term but improved after 2 years.
Bottomley et al. [158] 2005 Dose-intensives chemotherapy (CE + filgrastim) vs. CEF in locally advanced breast cancer Groups did not differ in progression free survival; lower QOL in intensified group at short term but no difference at long term.
Ahles et al. [159] 2005 Standard-dose systemic chemotherapy vs. local therapy only in long-term breast cancer survivors Lower overall QOL in chemotherapy group.
Peppercorn et al. [160] 2005 High-dose chemotherapy + ABMT vs. intermediate-dose chemotherapy in patients with stage II and III breast cancer Patients who received more intensive therapy experienced transient declines in QOL; by 12 months after, QOL was comparable between the 2 arms, regardless of therapy intensity, and many QOL areas were improved from baseline.
Semiglazov et al. [161] 2006 CMF + mistletoe lectin (PS76A2) vs. CMF + placebo PS76A2 improved QOL during and after chemotherapy.
Martin et al. [162] 2006 FAC vs. TAC or TAC + G-CSF in node negative breast cancer Lower QOL in patients treated with TAC. Addition of G-CSF improves QOL.
Hurria et al. [163] 2006 Anthracyclin-based chemotherapy or CMF in older women with breast cancer QOL maintained in both group.
Fallowfield et al. [164] 2006 EXE vs. TAM after 2–3 years of TAM in postmenopausal primary breast cancer Temporary decrease in overall QOL for EXE but no other differences.
Groenvold et al. [165] 2006 CMF vs. ovarian ablation CMF had more negative impact on QOL.
Cella et al. [166] 2006 ANA vs. TAM alone or in combination in postmenopausal breast cancer ANA and TAM had similar impact on QOL.
Liu et al. [167] 2006 DPPE + A vs. A in patients with advanced or metastatic breast cancer Patients on A alone had fewer disease and treatment adverse events and better QOL.
Karamouzis et al. [168] 2007 Chemotherapy vs. supportive care in metastatic patients QOL was better in patients receiving chemotherapy than those under supportive care.
Hopwood et al. [169] 2007 Adjuvant radiotherapy QOL and mental health were favorable for most patients about to start radiotherapy but younger age and receiving chemotherapy were significant risk factors for poorer QOL.
  1. Abbreviations
  2. C: Cyclophosphamide, M: Methotrexate, F: 5-fluorouracil, A: Doxorubcin, E: Epirubcin, T: Docetaxel, TAM: Tamoxifen, ANA: Anastrozole, EXE: Exemestane, QOL: Quality of life, DPPE: Tesmilifene, Granulocyte colony stimulating factor: G-CSF, CTCb: Cyclophosphamide, thiotepa, and carboplatin